Alexion Deal Adds Up For AstraZeneca's Rare Disease Specialist CFO
Marc Dunoyer Previously Led GSK's Orphan Operations
The proposed $39bn acquisition of Alexion by AstraZeneca has a particular interest for its chief financial officer Marc Dunoyer who recently spoke to Scrip about his extensive experience in the rare disease space.
You may also be interested in...
Pascal Soriot said AZ employees should be proud of the COVID-19 vaccine achievements so far, but conceded that manufacturing output would continue to lag.
Phase III trials of a number of late-stage investigational therapies are expected to read out during the second quarter of 2021, according to new analysis from Informa Pharma’s product pipeline database Biomedtracker. Some of the Phase III data could be transforming for a few of the less grand players in the pharma sector and here Scrip picks out some of the highlights to look out for in the months ahead.
Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.